ANIK Director Gets 14,164 RSUs; Ownership Now 50,258 Shares

Director equity grant highlighted in Form 4 filing On 20 June 2025, Anika Therapeutics (ticker: ANIK) director Glenn R. Larsen received an award of 14,164 restricted stock units (RSUs) at an exercise price of $0.

Rhea-AI Filing Summary

Director equity grant highlighted in Form 4 filing

On 20 June 2025, Anika Therapeutics (ticker: ANIK) director Glenn R. Larsen received an award of 14,164 restricted stock units (RSUs) at an exercise price of $0. Each RSU represents the right to one share of common stock. The units vest in full on the earlier of the 2026 annual shareholder meeting or 20 June 2026.

After the grant, Larsen’s direct beneficial ownership rises to 50,258 common shares. No sales, option exercises or other derivative transactions were reported. The filing reflects routine director compensation rather than an open-market purchase, therefore cash was not exchanged and there is no immediate impact on the company’s outstanding share count or cash position.

While the additional ownership marginally strengthens management–shareholder alignment, the transaction is typical for board-level remuneration and is not by itself a material catalyst for the stock.

Positive

• Director’s stake increases to 50,258 shares, modestly improving insider–shareholder alignment through additional equity ownership.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine RSU award; increases stake, limited market impact.

The Form 4 discloses a standard annual equity grant—14,164 RSUs—to director Glenn Larsen. Because the shares vest within a year and required no cash outlay, the filing signals alignment rather than a proactive valuation call. Ownership climbs to roughly 50 k shares, but no insider buying or selling occurred. Such compensation grants are customary and already reflected in equity-based expense projections. Consequently, I view the disclosure as neutral: modestly positive for governance yet unlikely to influence earnings, liquidity, or short-term trading dynamics.

Insider Trade Summary

Grant/Award: 14,164 shares

Grant/Award 1 txn

Insider Larsen Glenn R.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	14,164	$0.00	$0.00

Holdings After Transaction: Common Stock — 50,258 shares (Direct)

Footnotes (1)

1. F1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Anika Therapeutics (ANIK) shares did Glenn Larsen acquire?

He was awarded 14,164 restricted stock units, each convertible into one share of common stock.

What was the transaction price for the RSU grant?

The RSUs were granted at $0 cost as part of standard director compensation.

When will the RSUs granted on 20 Jun 2025 vest?

They vest in full on the earlier of the 2026 annual shareholder meeting or 20 Jun 2026.

What is Glenn Larsen’s total beneficial ownership after this filing?

Following the grant, Larsen beneficially owns 50,258 ANIK shares directly.

Did the filing disclose any insider sales or option exercises?

No. The Form 4 reports only the RSU grant; no sales or derivative exercises were listed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2025 - 05:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Larsen Glenn R.

(Last) (First) (Middle)

32 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		A		14,164(1)	A	$0	50,258	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.

	/s/ Glenn R. Larsen	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.